Navigation Links
Mardil Inc. Appoints Medical Device Veteran Daniel A. Pelak to Its Board of Directors
Date:2/19/2009

RESEARCH TRIANGLE PARK, N.C., Feb. 19 /PRNewswire/ -- Mardil Inc., a cardiac medical device company with novel technology for treating mitral valve regurgitation, today announced the appointment of Daniel A. Pelak to its board of directors.

Mr. Pelak's significant experience in the field of cardiac medical devices will serve as a guiding force for Mardil, a company that has rapidly advanced its unique device from the development stage to human trials within a span of 2 years, according to Gopal Muppirala, CEO and co-founder of Mardil.

"Dan has a long history as a senior executive in the medical device industry, garnering multiple successes in growing young companies and managing corporate operating divisions," said Jai Ramon, M.D., Mardil co-founder and professor of surgery and director of adult cardiac surgery and cardiothoracic surgical research at the University of Chicago. "He has a wealth of experience commercializing cardiac devices, and we look forward to adding someone with Dan's background to our board."

The Mardil device, called BACE (basal annuloplasty of the cardia externally), began first-in-human testing in India last month, and clinical trials will expand internationally in the third quarter of 2009. The BACE device serves as a tension band that encircles the heart and supports the exterior heart muscle. Its gentle pressure enables the leaflets of the mitral valve to open and close properly and thus prevents the backflow of blood into the left ventricle, a condition called mitral regurgitation. The device is designed to be less invasive, less costly, and to reduce side effects and mortality rates associated with current mitral valve repair and replacement techniques.

"The BACE device is truly a breakthrough technology that has the potential to change the way we treat heart valve disease," Pelak said. "I am excited to be affiliated with a company that has successfully developed a truly novel alternative to invasive valvular replacement, and I look forward to contributing my skills toward advancing this therapy."

Currently Mr. Pelak is senior advisor to the private equity firm Welsh, Carson, Anderson and Stowe. Previously he served as the CEO of InnerPulse Inc. and as the CEO of Closure Medical Corp. until its acquisition by Johnson & Johnson in 2005. Pelak began his career at Medtronic Inc., where he advanced through multiple management positions over a 20-year period. His executive positions at Medtronic included vice president of cardiovascular marketing as well as vice president and general manager of three operating divisions: Nortech, Cardiac Surgery Technology, and Perfusion Systems.

ABOUT MARDIL INC.

Mardil Inc. is a medical device company whose mission is to design, develop and market new and innovative patented technologies in the cardiac medical device field. Each device will fulfill an unmet need in cardiovascular medical procedures by improving upon existing technology or by designing new technology that more effectively treats cardiovascular conditions. The company's first product is a minimally invasive device that treats functional mitral valve regurgitation. The device is currently undergoing human trials.


'/>"/>
SOURCE Mardil Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Consorta Board Appoints Darrel Weatherford President and Chief Executive Officer
2. IMIA Interpreter Association Appoints Canada Representative
3. Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts
4. Hillenbrand Board of Directors Appoints Joe Loughrey as New Director
5. Gold Partners Appoints Larry Bell, M.D. President, Regulatory, Quality, Safety and Risk Management Services
6. USHIFU Appoints Mark Schoenberg, M.D. Chief Medical Officer
7. Physiotherapy Associates Appoints Daniel J. Connors Chief Executive Officer
8. WorldHeart Appoints New President and CEO
9. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
10. ORBIS International Appoints New President
11. Vigilan Appoints Robin Hand to VP of Customer Support
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... 2017 , ... Coveros, a leader in agile coaching services ... by the Center for Medicare and Medicaid Services (CMS). The Enterprise Agile Transformation ... Agile methodologies in a consistent and high value manner across CMS programs. Coveros ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... are now treating sleep apnea using cutting-edge Oventus O2Vent technology. As ... serious sleep disorder characterized by frequent cessation in breathing. Oral appliances can offer ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
Breaking Medicine Technology: